Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 8/20 | 0.37 |
| ▸ | CA1 | P00915 | 5/20 | 0.37 |
| ▸ | CA12 | O43570 | 2/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.37 |
| ▸ | CA7 | P43166 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 4/20 | 0.36 |
| ▸ | CA5A | P35218 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 7/20 | 0.35 |
| ▸ | MAOB | P27338 | 7/20 | 0.35 |
| ▸ | KDM1A | O60341 | 4/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3978109 | 0.70 | CA1 (0.31) | CA2CA1 | |
| SCHEMBL1500499 | 0.69 | KDM1A (0.33) | CA2CA1CA12CA7CA9 | |
| SCHEMBL8695942 | 0.68 | CA1 (0.32) | CA2CA1CA12CA14CA7 | |
| SCHEMBL28021247 | 0.68 | MAOB (0.34) | CA2CA1CA12CA14CA7 | |
| SCHEMBL4649386 | 0.67 | CA2 (0.37) | CA2CA1CA12CA14CA7 | |
| SCHEMBL394270 | 0.65 | MAOA (0.41) | MAOAMAOBKDM1ACYP3A4 | |
| SCHEMBL7364601 | 0.65 | — | — | |
| SCHEMBL15346092 | 0.64 | KDM1A (0.30) | MAOAMAOBKDM1A | |
| SCHEMBL31294910 | 0.64 | MAOA (0.37) | MAOAMAOBKDM1ACYP3A4 | |
| SCHEMBL5790163 | 0.63 | MAOA (0.38) | MAOAMAOBKDM1ACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090197836-A1 | Combination of FBPase Inhibitors and Antidiabetic Agents Useful for the Treatment of Diabetes | VAN POELJE PAUL D | 2009-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090197836-A1 | Combination of FBPase Inhibitors and Antidiabetic Agents Useful for the Treatment of Diabetes | FBP1, ALDOA, G6PC1 | CA2 974/4885CA1 2648/4885CA12 2664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.